AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01032408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Begrivac®
Description: 15 ug of HA antigen; non-adjuvanted; trivalent
Study NCT02480114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Therapy
Description: Receive usual oral health care
Study NCT02480114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Therapy
Description: Receive usual oral health care
Study NCT02480114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02480114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02480114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02480114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Acetaminophen
Description: Analgesia
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen
Description: Analgesia
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen
Description: Analgesia
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen
Description: Analgesia
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Transdermal Analgesia
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Transdermal Analgesia
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: NSAID Analgesia
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID Analgesia
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magic Mouthwash
Description: Oral Solution to treat mucositis
Study NCT02480114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magic Mouthwash
Description: Oral Solution to treat mucositis
Study NCT00437957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 Mg/m2/day for all Cohorts
Study NCT00437957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
Study NCT00437957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy
Description: Concurrently with Temozolomide and VPA
Study NCT03334981 — intervention group
Intervention type: PROCEDURE
Intervention: Concentrations in Meconium of Buprenorphine and Methadone
Description: buprenorphine or methadone concentration measurement
Study NCT01317160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Description: 6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
Study NCT01017042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine tablets
Description: colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
Study NCT02682485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro, metronidazole, neomycin combo
Description: During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
Study NCT02682485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Endoscopic Surveillance
Description: Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
Study NCT02682485 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Serial Endoscopic Surveillance
Description: Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
Study NCT02682485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
Study NCT02505191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's wort prolonged-release tablet 500 mg
Study NCT02505191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: St. John's wort film coated tablets 250 mg
Study NCT03954275 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00826995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
Study NCT01995825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand lamotrigine
Description: Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
Study NCT00826995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Educational Materials
Description: In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
Study NCT03139331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
Study NCT03139331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects.
Study NCT03139331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
Study NCT03911531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Exome Sequencing
Description: Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
Study NCT03911531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Genome Sequencing
Description: Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
Study NCT03882866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D-printed non-coplanar template
Description: 3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
Study NCT03882866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D-printed coplanar template
Description: 3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
Study NCT01467024 — intervention group
Intervention type: OTHER
Intervention: CDPHL Algorithm
Description: Supplemental testing algorithm performed by the CDPHL.
Study NCT01847872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV IM Needle
Study NCT01847872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV ID Needle
Study NCT01847872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV IM Device
Study NCT01847872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPV ID Device
Study NCT01135004 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracoscopic bullectomy
Description: Thoracoscopic wedge resection of the diseased lung
Study NCT02289521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~* Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~* Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation).
Study NCT02289521 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~* Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~* Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation).
Study NCT02074761 — intervention group
Intervention type: DEVICE
Intervention: SImmetry
Description: The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion.
Study NCT02249260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Group-based high-intensity aerobic interval training and lifestyle counseling
Study NCT00646191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
Study NCT00646191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg weekly through Week 48 (OL Week 12 - 48)
Study NCT00646191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
Study NCT03463044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: Continous i.v. infusion
Study NCT03463044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04573153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Metabolic cofactor supplementation
Description: Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
Study NCT04573153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine + Sorbitol
Description: Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
Study NCT04519216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telesimulation
Description: Telesimulation educational intervention
Study NCT04519216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telesimulation
Description: Telesimulation educational intervention
Study NCT04603313 — intervention group
Intervention type: OTHER
Intervention: tele-advice system
Description: The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
Study NCT04017624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Truck with stipend
Description: Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location.
Study NCT03972046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-Vec)
Description: Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
Study NCT03972046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib (BRAF Inhibitor)
Description: Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
Study NCT03251235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy
Study NCT01667835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: 12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
Study NCT01156025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV550
Description: Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
Study NCT01156025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
Study NCT02293967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303
Study NCT00949923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tea capsule
Description: 3 tea capsules daily for 3 weeks
Study NCT02557451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT02557451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of gas
Study NCT02557451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injections of an antiangiogenic
Study NCT04017624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE screening and referral
Description: The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
Study NCT02203942 — intervention group
Intervention type: OTHER
Intervention: NAAT testing
Description: comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
Study NCT01995825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic lamotrigine
Description: Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
Study NCT04988646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 MG
Description: Administered with 240 mL of water
Study NCT04988646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 MG
Description: Administered with 240 mL of water
Study NCT02382770 — intervention group
Intervention type: PROCEDURE
Intervention: Open abdomen procedure
Description: Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
Study NCT01925300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab
Study NCT01925300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab
Study NCT04988646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zovirax 200 MG Tablet
Description: Administered with 240 mL of water
Study NCT04988646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zovirax 400 MG Tablet
Description: Administered with 240 mL of water
Study NCT03036046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 with fluconazole low dose
Description: adverse events
Study NCT03036046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 with fluconazole high dose
Description: adverse events
Study NCT03036046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 with posaconazole
Description: adverse events
Study NCT02951728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT03623815 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered.
Study NCT03578861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia related mobility and counseling
Description: The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments.
Study NCT03809143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
Study NCT02582502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: The only intervention given will be 100% oxygen under hyperbaric pressure.
Study NCT02582502 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperbaric Oxygen
Description: The only intervention given will be 100% oxygen under hyperbaric pressure.